Open AccessValbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Author(s) -
Citrome Leslie
Publication year - 2017
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.12964
Subject(s) - medicine , tardive dyskinesia , discontinuation , tolerability , placebo , clinical trial , adverse effect , psychiatry , alternative medicine , pathology , schizophrenia (object oriented programming)
The objective of this systematic review was to describe the efficacy, tolerability, and safety of valbenazine for the treatment of tardive dyskinesia (TD).